IRIDEX (IRIX) Q4 2024 earnings summary

Executive summary

• Completed a cost reduction program in Q4 2024, stabilizing operations and achieving positive adjusted EBITDA, with net loss narrowing to $0.8 million from $3.0 million year-over-year.

• Secured a $10 million strategic investment from Novel Innovations at a premium, with an additional $10 million available for future growth.

• Q4 2024 revenue was $12.7 million, up 2% year-over-year; full-year 2024 revenue was $48.7 million, down 6% year-over-year.

• Strategic review and transaction discussions remain ongoing amid heightened industry M&A activity.

• Full-year net loss improved to $8.9 million from $9.6 million.

Financial highlights

• Q4 2024 gross profit reached $5.6 million (44.0% margin), up from $4.9 million (39.2% margin) year-over-year.

• Operating expenses declined to $6.1 million in Q4, down 24% year-over-year; full-year OPEX was $27.8 million, down 13%.

• Net loss per share for Q4 was $0.05 (vs. $0.18 year-over-year); full-year net loss per share was $0.54 (vs. $0.59 year-over-year).

• Achieved positive adjusted EBITDA of $0.4 million in Q4, a $2.4 million improvement year-over-year; full-year adjusted EBITDA loss improved to -$5.1 million from -$7.0 million.

• Cash and equivalents at year-end were $2.4 million, excluding the $10 million Novel investment.

Outlook and guidance

• Expects to achieve cash flow breakeven and positive adjusted EBITDA in 2025, with revenue in line with 2024.

• Focus on modernizing manufacturing to reduce costs and increase capacity.

• Anticipate increased utilization from LCD changes affecting glaucoma treatments.

• Q1 2025 results will be pre-announced in April to facilitate insider trading window and transparency.

• Plans to maintain cost discipline and deliver positive cash flow for 2025.